NASDAQ · Biotechnology · USD

Kalaris Therapeutics, Inc. (KLRS) Stock Analysis

Kalaris Therapeutics, Inc. (KLRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KLRS

$3.90

−$0.04 (−1.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KLRS with… →

KLRS Key Statistics

As of Sep 4, 2026

Trading

Open: $3.91
Previous Close: $3.94
Day's Range: 3.82–3.95
52-Week Range: 3.03–11.88
Volume: 23.90K

Valuation

Market Cap: $92.84M
P/E Ratio: unprofitable
EPS (ttm): −1.90

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$43.44M
Profit margin: 0.00%
Shares Outstanding: 23.80M
1-Year Return: −16.31%

Dividend and dates

Avg Volume: 255.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KLRS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+51.40%−66.34%−60.36%−86.74%−38.24%−12.63%−53.79%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−53.79%
2025	−12.63%
2024	−38.24%
2023	−86.74%
2022	−60.36%
2021	−66.34%
2020 (partial year)	+51.40%

As of September 4, 2026.

KLRS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$43.44M	—
2024	$0.00	−$69.17M	—
2023	$0.00	−$14.70M	—
2022	$0.00	−$15.49M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$46.15M	−$43.44M	—
2024	$0.00	—	−$51.73M	−$69.17M	—
2023	$0.00	—	−$13.46M	−$14.70M	—
2022	$0.00	—	−$14.01M	−$15.49M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KLRS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	KLRS	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kalaris Therapeutics, Inc. (KLRS) carries a market capitalisation of $92.84M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

Over the past 52 weeks the price has ranged from $3.03 to $11.88. KLRS last closed at $3.90 on September 4, 2026. That is −$0.04 (−1.02%) against the previous close. The latest close sits 28.71% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $43.44M. Profit margin runs at 0%. Trailing earnings per share are −1.9.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Annualized volatility over the trailing 6 years is 95.41%. Over the trailing twelve months the price has returned −16.31%. Measured over 5 years, that is −61.56% a year compounded.

Growth & Income

No dividend is on file for KLRS.

Across the complete calendar years on file, 2025 returned −12.63% and 2023 returned −86.74%. Of the 5 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −53.79% year to date.

Peer Comparison

Kalaris Therapeutics, Inc. (KLRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kalaris Therapeutics, Inc.	KLRS	$92.84M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Kalaris Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Visit website →